BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — China Revenue Growth YoY by Quarter
BRUKINSA — China Revenue Growth YoY (%) (%)
BeOne Medicines BRUKINSA — China Revenue Growth YoY: 16.7% in Q2 2026, down 14.1 pts from a year earlier.
Latest, Q2 2026
16.7%
Period ended Jun 30, 2026
Change on a year earlier
-14.1 pts
30.8% in Q2 2025
History
15 quarters
Since Q3 2021
Sources
15
Documents cited below
Where the Q2 2026 figure comes from
“BRUKINSA sales in China totaled $97.2 million, representing growth of 16.7%”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — China Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 16.7% | -14.1 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 15.9% | -25.4 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 36.2% | -6.8 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 30.8% | -0.4 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 41.3% | +21.9 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 43.0% | +22.2 pts | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 31.2% | -1.0 pts | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 19.4% | -24.1 pts | Form 10-Q (filed 2024-05-08) ↗ |
| Q3 2023 | Sep 30, 2023 | 20.8% | -2.1 pts | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 32.2% | -6.5 pts | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 43.5% | -136.5 pts | Form 10-Q (filed 2023-05-04) ↗ |
| Q3 2022 | Sep 30, 2022 | 22.9% | -200.1 pts | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 38.7% | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 180.0% | – | Form 10-Q (filed 2022-05-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 223.0% | – | Form 10-Q (filed 2021-11-04) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — China Revenue Growth YoY (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-cn-yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.